PDCD1LG2 and melanoma: In the discovery cohort, PD‐L2 levels on EV membranes demonstrated a stronger association with response and prognosis in mucosal melanoma patients treated with anti‐PD‐1 plus anti‐angiogenesis therapy than PD‐L1.